Combination immunotherapy with a CpG oligonucleotide ( 1018 ISS ) and rituximab in patients with non-Hodgkin lymphoma : increased interferon-/ – inducible gene expression , without significant toxicity

@inproceedings{Friedberg2004CombinationIW,
  title={Combination immunotherapy with a CpG oligonucleotide ( 1018 ISS ) and rituximab in patients with non-Hodgkin lymphoma : increased interferon-/ – inducible gene expression , without significant toxicity},
  author={Jonathan W. Friedberg and Helen S. Kim and Mary McCauley and Edith M Hessel and Paul Francis George Sims and David C. Fisher and Lee M. Nadler and Robert Lee Coffman and Arnold Stephen Freedman},
  year={2004}
}
CpG oligodeoxynucleotides (CpG-ODNs) affect innate and adaptive immune responses, including antigen presentation, costimulatory molecule expression, dendritic cell maturation, and induction of cytokines enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). We conducted a phase 1 study evaluating 4 dose levels of a CpG-ODN (1018 ISS) with rituximab in 20 patients with relapsed non-Hodgkin lymphoma (NHL). Patients received CpG once a week for 4 weeks beginning after the second of 4… CONTINUE READING